- Jun 24, 2022
Study shows that genomic tumor profiling of pediatric tumors can enhance clinical care
Results of a study of molecular tumor profiling in young patients revealed a high rate of genetic alterations with potential for impacting clinical care, including clarifying diagnoses and treatment with matched, precision cancer drugs. Read more: https://medicalxpress.com/news/2022-06-genomic-tumor-profiling-pediatric-tumors.html
- Jun 23, 2022
Pushing T cells down "memory lane" may improve cancer therapy
Scientists at St. Jude Children's Research Hospital identified proteins that help decide T cell fate and used the finding to improve CAR-T cell therapy in a solid tumor model. Read more: https://www.prnewswire.com/news-releases/pushing-t-cells-down-memory-lane-may-improve-cancer-therapy-301573210.html
- Jun 20, 2022
Previous Cancer Not Seen to Raise Thyroid Surgery Risks for Children
Children successfully treated for a cancer who undergo thyroid surgery for a secondary thyroid disease have a similar risk of surgical complications, such as permanent hypoparathyroidism, as children without a previous cancer, a single-center study in the U.S. shows. Read more: https://hypoparathyroidismnews.com/news/thyroid-surgery-risks-not-higher-children-prior-cancer-study/
- Jun 16, 2022
Bortezomib extends survival of children with newly diagnosed T-cell lymphoblastic lymphoma
The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young adults with T-cell lymphoblastic lymphoma, according to phase 3 study results published in Journal of Clinical Oncology. Read more: https://www.healio.com/news/hematology-oncology/20220614/bortezomib-extends-survival-of-children-with-newly-diagnosed-tcell-lymphoblastic-lymphoma
- Jun 14, 2022
A drug and a DNA variant increase heart disease risk in cancer survivors
Scientists from St. Jude Children's Research Hospital have identified a genetic variant associated with substantially increased risk of heart disease in survivors of childhood cancer treated with the chemotherapy doxorubicin. Read more: https://medicalxpress.com/news/2022-06-drug-dna-variant-heart-disease.html
- Jun 13, 2022
Researchers Identify RAD21 Variants in Pediatric Lymphoblastic Leukemia or Lymphoma
A recent study involving children with hematologic malignancies has suggested that mutations in a portion of a cohesin gene known as RAD21 may have relevance to pediatric lymphoblastic leukemia or lymphoma. Findings of the study were reported in the International Journal of Molecular Sciences. Read more: https://www.hematologyadvisor.com/home/topics/leukemia/rad21-variants-pediatric-leukemia/
- Jun 10, 2022
Adult survivors of childhood cancer often undertreated for cardiovascular risk factors
Adults who survive childhood cancer have a higher risk of cardiovascular disease than the general population, yet they are 80% more likely to be undertreated for several cardiovascular risk factors: hypertension (also called high blood pressure), diabetes and high cholesterol, according to new research published in the Journal of the American Heart Association. Read more: https://medicalxpress.com/news/2022-06-adult-survivors-childhood-cancer-undertreated.html
- Jun 9, 2022
Dabrafenib + Trametinib Improve Overall Response Rates in Pediatric Patients with Low-Grade Gliomas
The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600 mutation–positive low-grade gliomas. Read more: https://ascopost.com/news/june-2022/dabrafenib-plus-trametinib-improve-overall-response-rates-vs-standard-of-care-chemotherapy-in-pediatric-patie
- Jun 8, 2022
Study confirms the benefits of 'bridge therapy' for some children with high-risk neuroblastoma
New findings published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, show that a "bridge therapy" between induction and consolidation treatments may benefit patients with this high-risk neuroblastoma. Read more: https://www.news-medical.net/news/20220606/Study-confirms-the-benefits-of-bridge-therapy-for-some-children-with-high-risk-neuroblastoma.aspx
- Jun 7, 2022
Study identifies best treatment for rare childhood cancer
High doses of drug called ifosfamide are the best way to treat a cancer of children which affects bones and soft tissues, compared to three other treatments, according to University of Manchester researchers. Read more: https://www.manchester.ac.uk/discover/news/study-identifies-best-treatment-for-rare-childhood-cancer/